Emily Field, Barclacys head of European pharmaceuticals equity research, joins 'Squawk Box' to discuss Novo Nordisk's ...

Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Drugmaker Novo Nordisk expects a recovery of Wegovy weight-loss drug ...

U.S.-listed shares of Novo Nordisk are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered ...

Obesity drugmaker Novo Nordisk cut its sales forecasts on Wednesday for the first time since the launch of its Wegovy ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

The company has seen sales hit by alternative compounded versions of its blockbuster weight-loss and diabetes drugs, ...

Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Honeywell ...

Shares in Novo Nordisk were still up after Q1 2025 witnessed a total revenue jump by 18%, compared to Q1 2024.

Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...

Novo reported $11.9 billion in revenues, in line with Wall Street's estimates, and beat on adjusted earnings per share (EPS) ...

Teva Pharmaceutical Industries reported a slightly larger than expected rise in first-quarter profit, helped by strong sales ...